Neuroprotective Therapy with Citicoline (Ceraxon) in Patients with Ischemic Stroke
- 95 Downloads
The dynamics of neurological symptoms were assessed using the Scandinavia Stroke Scale and functional disease outcomes with the Barthel index and modified Rankin scale in 89 patients during the acute period of ischemic stroke of moderate severity, whose treatment included citicoline (Ceraxon) i.v. and p.o. The results were compared with those from a reference group (52 patients) selected in terms of clinical and demographic parameters, who received similar treatment without citicoline. By discharge from hospital (days 21–24 of illness), there was significantly (p < 0.05) greater recovery in the study group. The efficacy of citicoline was significantly (p < 0.05) greater in patients aged less than 70 years and when citicoline was given in the first hours of illness.
Keywordsischemic stroke cytoprotective therapy citicoline
Unable to display preview. Download preview PDF.
- 1.E. I. Gusev, V. I. Skvortsova, and L. V. Stakhovskaya, “The problem of stroke in the Russian Federation: a time for positive actions,” Zh. Nevrol. Psikhiat., 107, No. 6, 4–10 (2007).Google Scholar
- 4.E. I. Gusev, A. N. Boiko, V. L. Baratashvili, et al., “Results obtained using citicoline (Ceraxon) in patients with acute cerebral stroke,” Med. Krit. Sostoyanii, 2, 42–47 (2010).Google Scholar
- 7.G. Trifiró and E. Spina, “Age-related changes in pharmacodynamics: focus on drugs acting on central nervous and cardiovascular systems,” Curr. Drug. Metab., 12, No. 4, 542–549 (2011).Google Scholar
- 19.M. M. Odinak and I. A. Voznyuk, “The role of exogenous choline in protection and recovery of brain matter in stroke. Quality of life,” Meditsina, 21, No. 4, 1–7 (2007).Google Scholar